A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

Recruiting now · Phase 1/Phase 2 · Has a placebo group

Conditions studied: SLE

In brief

To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).

Key facts

Study ID

NCT06182969

Run by

Ascentage Pharma Group Inc.

People needed

40

Starts

2024-08-09

Expected to finish

2026-12-01

Last updated by the study team

2025-12-16

Who can join

Age: 18 and older, up to 65. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• 1. Diagnosis of systemic lupus erythematosus for at least 6 months.
• 2. On stable treatment for systemic lupus erythematosus before first dose at least 28 days.
• 3. SLEDIA-2000 score: 4-12
• 4.Other than systemic lupus erythematosus, subject should be in general good health.

You may not qualify if…

• 1. Severe systemic lupus erythematosus.
• 2. Significant autoimmune disease other than lupus.
• 3. Significant, uncontrolled or unstable disease in any organ.

Where it is running

• Renji Hospital Shanghai Jiaotong University School of Medical — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.